NASDAQ$NVCT
Nuvectis Pharma Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported fiscal year 2022 financial results and business highlights.
Nuvectis Pharma reported its financial results for the fiscal year 2022. The company's cash, cash equivalents, and short-term investments were $20.0 million as of December 31, 2022, and the net loss was $19.1 million for the year ended December 31, 2022.
- Advanced the Phase 1a dose escalation study for NXP800 in patients with various advanced solid tumors.
- FDA granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma.
- ENGOT and GOG-F will lead the upcoming Phase 1b clinical trial in ARID1a-mutated ovarian carcinoma.
- Progress made toward submission of an IND and commencement of the Phase 1 clinical trial for NXP900, expected in 1H2023.
Headline financials
Revenue & EPS history
Nuvectis Pharma · Revenue · Quarterly
$149K
Forward guidance
Nuvectis expects to continue the momentum for both programs into the second half of 2024.
Tailwinds
- NXP800 Phase 1a dose escalation study progressing.
- NXP800 granted FDA Fast Track Designation.
- ENGOT and GOG-F to lead NXP800 Phase 1b clinical trial.
- NXP900 IND submission and Phase 1 clinical trial expected in 1H2023.
- Sufficient working capital to continue momentum for both programs into the second half of 2024.
Headwinds
- Uncertainties related to clinical trial outcomes.
- Risks associated with drug development and regulatory approvals.
- Potential delays in IND submission and trial commencement.
- Dependence on successful collaborations and partnerships.
- Market and other conditions could impact forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+2.4%
Avg return
Earnings day
+7.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
65%
13 / 20 earnings
Positive
+29.2%
Q3 2024
Best reaction
-14.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.4% | +31.6% | +8.8% | |
| Q4 2026 | +0.5% | +0.2% | +3.3% | |
| Q3 2025 | -7.9% | -3.5% | +6.1% | |
| Q2 2025 | -5.4% | -17.7% | -10.6% | |
| Q1 2025 | +6.4% | +8.3% | -9.4% | |
| Q4 2024 | -5.8% | -9.1% | +31.1% | |
| Q3 2024 | +29.2% | +71.3% | -24.6% | |
| Q1 2024 | -14.9% | -15.3% | -13.6% | |
| Q4 2023 | -4.5% | -0.4% | -25.1% | |
| Q3 2023 | -7.9% | -6.6% | -8.4% | |
| Q2 2023 | +1.4% | +1.1% | -7.0% | |
| Q1 2023 | +5.8% | +6.3% | +14.0% | |
| Q4 2022 | -7.1% | -9.5% | +9.2% | |
| Q3 2021 | +0.9% | -3.5% | +7.7% | |
| Q3 2022 | +0.9% | -3.5% | +7.7% | |
| Q2 2021 | +1.1% | +10.1% | -0.6% | |
| Q2 2022 | +2.6% | -3.0% | -3.7% | |
| Q1 2021 | +18.8% | +28.8% | -24.4% | |
| Q4 2021 | +18.8% | +33.6% | -15.6% | |
| Q1 2022 | +5.4% | +25.2% | -19.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro